Latest Advances in MASH Therapy: Resmetirom and Semaglutide, Evaluation in the STAM Model
The FDA approved two therapies for MASH: the oral agent Resmetirom in 2024 and the GLP-1 receptor agonist Semaglutide on August 15, 2025 (FDA announcement). Resmetirom reduces liver fat, while Semaglutide improves metabolism and slows disease progression, demonstrating distinct mechanisms of action. These approvals represent a significant and welcome step forward in MASH treatment, and both agents are expected to become standards of care (SOC) in the future. Our STAM mouse model includes evaluation data for both drugs, supporting preclinical research in this field.
Please contact us for further details.